Company Focus
Icon
Latest Icon News
Biotechnology
Irish contract research organization ICON has retained its position as the most active CRO worldwide in the first quarter of 2025, according to a new analysis by GlobalData. 16 May 2025
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need.
Latest News & Features of interest to Icon
Pharmaceutical
They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data presented by Eli Lilly—they have gone up against one another. 13 May 2025
Biotechnology
Swedish biotech Hansa Biopharma has appointed Maria Törnsén as chief operating officer and president US, strengthening its commercial leadership ahead of key milestones for its kidney transplant drug Idefirix (imlifidase). 13 May 2025
Pharmaceutical
Denmark’s Novo Nordisk has presented data at the European Congress of Obesity (ECO) showing that Wegovy (semaglutide injection) 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 37% in adults with overweight and obesity and cardiovascular (CV) disease, compared to placebo, on top of standard of care, within the first three months of treatment. 13 May 2025
Pharmaceutical
German life sciences company Bayer presented its first-quarter financial results and latest guidance for 2025 on Tuesday. 13 May 2025
Pharmaceutical
Hungary’s largest drugmaker Gedeon Richter has announced its financial results for the first quarter of 2025, sending its shares up 2.2% to 26.46 euros. 13 May 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Adzynma (apadamtase alfa/cinaxadamtase alfa; rADAMTS13), the first UK treatment to treat congenital thrombotic thrombocytopenic purpura (CTTP) in patients of all ages. 13 May 2025
Biotechnology
Swiss pharma giant Roche, the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, today announced statistically-significant final overall survival (OS) results from the phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer. 13 May 2025
Biotechnology
Swiss pharma giant Roche is investing $280 million to build a new biopharma manufacturing facility in Shanghai, as it doubles down on its commitment to the Chinese market. 12 May 2025
Pharmaceutical
Chinese biotech Minghui Pharmaceutical has sold certain rights to its experimental cancer drug MHB088C to Qilu Pharmaceutical in a licensing deal worth up to $177 million. 12 May 2025
Biotechnology
US pharma firm BioMarin Pharmaceutical saw its shares rise nearly 4% to $61.09 this morning, after it released positive new data for its Voxzogo (vosoritide). 12 May 2025
Latest In Brief for Icon
Biotechnology
The Indian subsidiary of UK pharma major AstraZeneca has announced a Central Drugs Standard Control Organization (CDSCO) approval to import for sale and distribution of trastuzumab deruxtecan concentrate for solution for infusion 100mg for an additional indication, according to a Healthcare Radius report. 12 May 2025
Latest Relevant Ones To Watch News
California’s BioMarin Pharmaceutical is to acquire Inozyme Pharma or $4 per share in an all-cash transaction for a total consideration of approximately $270 million. 16 May 2025
30 April 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze